Financial Results | Artelo Biosciences 2025 Q1 Net Loss USD 2.37 Million

Artelo Biosciences(ARTL) posted the Q1 of its 2025 financial results on 5/13/2025, reporting net loss of USD 2.37 million in the first quarter, narrowing 4.47% from USD -2.48 million year over year. The EPS is USD -0.72 in the frist quater, compare with USD -0.78 last period.

[Detailed Data]

Million USD	Q1 2025	Q4 2024	Q3 2024	Q4 2024
Total Operating Expenses	2.37	3.81	1.20	3.81
Operating Income	-2.37	-3.81	-1.20	-3.81
Net Income	-2.37	-3.78	-1.13	-3.78
Net Income Attributable to Common Shareholders	-2.37	-3.78	-1.13	-3.78
EPS(USD)	-0.72	-1.1515	-0.35	-1.1515

[Company Profile]
Artelo Biosciences, Inc. was incorporated in the State of Nevada on May 2, 2011. The company is a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signalling pathways, including the endocannabinoid system (the “ECS”), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body.